Novo Nordisk's Victoza combination trial shows positive results

A combination of the Danish diabetes care giant Novo Nordisk's (NOV: N) Victoza (liraglutide), drug to treat type 2 diabetes, has demonstrated positive results, a trial has shown.

The results of the trial for Victoza and lixisenatide (Sanofi's Lyxumia), both in combination with metformin, were announced at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.

Professor Michael Nauck, principal investigator of the trial, said: “The significant difference in blood glucose control between liraglutide and lixisenatide reported in the LIRA-LIXI trial reinforces the value of liraglutide as an efficacious treatment for those with type 2 diabetes otherwise treated with oral glucose-lowering drugs. Many people living with type 2 diabetes remain uncontrolled and it is crucial for these patients to gain control of their blood glucose levels to help prevent further complications from this disease.”